AP NEWS

UPDATE -- Cellworks to Present 10 Abstracts at 2018 American Society of Hematology Annual Meeting

November 19, 2018

SAN JOSE, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a leader in Precision Medicine and a global pioneer of Therapy Response Index (TRI) technology, today announced that results from using its genomics-informed Computational Biology Modeling technology (CBM) to predict drug response within specific cancer tumors will be featured as 10 poster presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition held December 1-4, 2018 in San Diego, California.

“Over the past year, we have completed many studies using our AI-driven biosimulation technology to predict drug responses for tumors based the genomic data of each cancer patient,” said Yatin Mundkur, CEO of Cellworks. “The consistent high accuracy of these studies demonstrates tremendous promise for using AI-driven biosimulation to match the best therapy to individual patients the first time. This approach avoids the side-effects, costs and risks associated with nonresponsive treatments, and ultimately saves lives. We look forward to sharing the results of these studies with oncologists and cancer researchers at this year’s ASH meeting.”

POSTER PRESENTATIONS

Title: Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This CohortDate & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PMSession: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Abstract: 1539Location: San Diego Convention Center – Hall GH Presenter: Shireen Vali

Title: WT1 and BCORL1 Identified by Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)Date & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PMSession: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Abstract: 1538Location: San Diego Convention Center - Hall GH Presenter: Shireen Vali

Title: Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project StudyDate & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PM Poster Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Abstract: 1540Location: San Diego Convention Center – Hall GH Presenter: Shireen Vali

Title: Computational Modeling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment OutcomeDate & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PMSession: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I Abstract: 1911Location: San Diego Convention Center - Hall GH Presenter: Aneel Paulus

Title: Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project StudyDate & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PMSession: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster IAbstract: 1541Location: San Diego Convention Center - Hall GH Presenter: Shireen Vali

Title: Clinical Validation of Treatment Response Predictions Using a Genomics Driven Computational Biology Modeling Multiple Myeloma AlgorithmDate & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PMSession: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I Abstract: 1893Location: San Diego Convention Center – Hall GH Presenter: Justin King

Title: Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical StudyDate & Time: Sunday, December 2, 2018 from 6:00 PM-8:00 PMSession: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II Abstract: 3086Location: San Diego Convention Center – Hall GH Presenter: Shireen Vali

Title: Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support SystemDate & Time: Sunday, December 2, 2018 from 6:00 PM-8:00 PM Poster Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II Abstract: 3087Location: San Diego Convention Center - Hall GH Presenter: Lubomir Minarik

Title: Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modeling of Genomics and ProteomicsDate & Time: Sunday, December 2, 2018 from 6:00 PM-8:00 PMSession: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II Abstract: 3193Location: San Diego Convention Center – Hall GH Presenter: Shireen Vali

Title: AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine WorkflowDate & Time: Monday, December 3, 2018 from 6:00 PM-8:00 PMSession: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III Abstract: 4034Location: San Diego Convention Center - Hall GH Presenter: Shireen Vali

Cellworks is transforming personalized cancer therapy through AI-driven biosimulation software models that represent bio molecular and physiological pathways using the genomic data of each patient. Cellworks personalized medicine predictions help transform lives through the early adoption of successful therapies, while saving time and cost across the healthcare ecosystem. Cellworks also benefits the biopharma industry through virtual clinical trials, improved target identification, lead validation and the ability to repurpose and rescue drugs.

About Cellworks Group, Inc. Cellworks Group, Inc. is a world leader in Precision Medicine in the key therapeutic areas of Oncology and Immunology. Cellworks’ unique AI-driven biosimulation platform is a unified representation of biological knowledge, curated from heterogeneous datasets, applied to finding cures. Backed by Sequoia Capital and Artiman Ventures, Cellworks has the world’s strongest trans-disciplinary team of molecular biologists, cellular pathway modelers, and software technologists working towards a common goal – attacking serious diseases to improve the lives of patients. The company is based in San Jose, California and has a research and development facility in Bangalore, India. For more information, visit www.cellworks.life, and follow us on Twitter @cellworkslife.

All trademarks and registered trademarks in this document are the properties of their respective owners.

Media Contacts:Barbara ReichertReichert Communications, LLC Barbara@reichertcom.com 650-548-1002

Michele Macpherson, Chief Business OfficerCellworks Group, Inc. michele.macpherson@cellworksgroup.com

AP RADIO
Update hourly